AAV with GFAP(0.7) promoter driven CreERT2

Name 
AAV-GFAP(0.7)-CreERT2-WPRE
Cat No 
VB4895
Availability
3 weeks

This AAV expresses CreERT2 driven by an astrocyte GFAP(0.7) promoter.

This 0.7 Kb novel GFAP promoter was constructed by ligating several key regulatory elements of the 2.2Kb human GFAP promoter. It drives essentially the same expression pattern as the parental 2.2 Kb GFAP promoter but with two-fold greater activity.

A mutated form of estrogen ligand-binding domain (ERT2) that binds to synthetic antagonists (such as tamoxifen or its derivative 4-hydroxy-tamoxifen) but not to circulating estrogen, was fused to the Cre recombinase (Cre) to create CreERT2 (also known as “inducible Cre”). When tamoxifen binds to CreERT2, it induces a conformational change of CreERT2, leading to its nuclear translocation, followed by Cre/Lox-mediated recombination.

VB4895
AAV-GFAP(0.7)-CreERT2-WPRE

Ready-to-use AAV expressing CreERT2 driven by an astrocyte GFAP(0.7) promoter. Available in AAV1, AAV2, AAV5, AAV6, AAV8, AAV9, AAV-DJ and other serotypes.

Request a Quote

Product Details

AAV Serotype
Available in AAV1, AAV2, AAV3, AAV5, AAV6, AAV8, AAV9, AAV-DJ, AAV-DJ8, AAV-DJ9 and other wildtype/synthetic AAV capsids
AAV ITR
AAV2
Promoter
GFAP(0.7) (astrocyte)
Storage Buffer
PBS/5% Glycerol
Titer
1x10^13 GC/ml
Viral Backbone
Recombinant AAV
Volume (µL)
200

About Storage Conditions

All our viral products should be kept at -80°C. At this temperature, the virus will remain stable for 6-12 months (and in some cases, up to 2 years). Once thawed, the product can be stored at 4°C for 2-3 weeks without significant loss of biological activity. We recommend aliquoting your vectors into low protein binding tubes upon receipt. This helps avoid repeated freeze-thaw cycles, as well as prevent loss of virus. To maintain accurate titer, aliquot in at least 20ul per tube.